Login / Signup

CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling.

Kate L HenryDebra KellnerBekim BajramiJohn E AndersonMercedes BeynaGovinda BhisettiThomas O CameronAndrew G CapacciAndrea Bertolotti-CiarletJun FengBenbo GaoBrian HopkinsTracy JenkinsKejie LiTricia May-DrackaParamasivam MuruganRu WeiWeike ZengNorm AllaireAlan BucklerChristine LohPeter JuhaszBrian LucasKatelin A EnnisElisabeth VollmanEllen Cahir-McFarlandErik C HettMichelle L Ols
Published in: Science signaling (2018)
Members of the family of nuclear factor κB (NF-κB) transcription factors are critical for multiple cellular processes, including regulating innate and adaptive immune responses, cell proliferation, and cell survival. Canonical NF-κB complexes are retained in the cytoplasm by the inhibitory protein IκBα, whereas noncanonical NF-κB complexes are retained by p100. Although activation of canonical NF-κB signaling through the IκBα kinase complex is well studied, few regulators of the NF-κB-inducing kinase (NIK)-dependent processing of noncanonical p100 to p52 and the subsequent nuclear translocation of p52 have been identified. We discovered a role for cyclin-dependent kinase 12 (CDK12) in transcriptionally regulating the noncanonical NF-κB pathway. High-content phenotypic screening identified the compound 919278 as a specific inhibitor of the lymphotoxin β receptor (LTβR), and tumor necrosis factor (TNF) receptor superfamily member 12A (FN14)-dependent nuclear translocation of p52, but not of the TNF-α receptor-mediated nuclear translocation of p65. Chemoproteomics identified CDK12 as the target of 919278. CDK12 inhibition by 919278, the CDK inhibitor THZ1, or siRNA-mediated knockdown resulted in similar global transcriptional changes and prevented the LTβR- and FN14-dependent expression of MAP3K14 (which encodes NIK) as well as NIK accumulation by reducing phosphorylation of the carboxyl-terminal domain of RNA polymerase II. By coupling a phenotypic screen with chemoproteomics, we identified a pathway for the activation of the noncanonical NF-κB pathway that could serve as a therapeutic target in autoimmunity and cancer.
Keyphrases